Nathalie Mesgouez‐Nebout

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.3K citations

Medicine, Oncology, Surgery +17

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Thierry Conroy, Florence Castan, Pierre-Luc Etienne et al. · Annals of Oncology · 2024 · 192 citations · Full text

Medicine, Oncology, Surgery +17

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy, Najib Lamfichekh, Pierre-Luc Etienne et al. · Journal of Clinical Oncology · 2020 · 177 citations

Medicine, Oncology, Surgery +17

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy, Pierre-Luc Etienne, Emmanuel Rio et al. · Journal of Clinical Oncology · 2023 · 109 citations

Medicine, Oncology, Surgery +17

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

Maud Kamal, Sonia Lameiras, Marc Deloger et al. · British Journal of Cancer · 2020 · 89 citations · Full text

Medicine, Molecular Biology, Oncology +17